Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) plans to launch zanubrutinib in India under the brand name BRUKINSA after receiving approval from the head of the local drug regulator, according to a Monday filing on the Indian bourses.
Developed by BeOne Medicines (formerly BeiGene), BRUKINSA is the first Bruton's tyrosine kinase (BTK) inhibitor approved in India for five blood cancers, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.